Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bavarian Nordic, Inc.
ClinicalTrials.gov Identifier:
NCT01322490
First received: March 23, 2011
Last updated: December 22, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2016
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)